rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AORT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Artivion (AORT) Stock Looks About Right Following Nexus Launch Preparations

      Artivion has seen its share price fall sharply over the past year, even as the business reports higher revenue and prepares new products for market. With the stock now trading around US$20.64, the key question is whether that price still lines up with what the company is generating in sales. The share price has declined 54.1% over the past year, which puts the focus squarely on whether the current market value is still in step with Artivion's revenue base. Recent double digit revenue growth,...

      Nov 10Yahoo FinanceAORTCRY
      Is Artivion (AORT) Undervalued Following Mixed Earnings And A Return To Losses?
      Nov 7Yahoo FinanceAORT
      Artivion Q3 Earnings Call Highlights
      Nov 7Yahoo FinanceAORTCRY
      Canaccord cuts Artivion stock price target on revenue outlook
      Nov 6Investing.comAORTCRY
      Artivion Inc (AORT) (Q3 2026) Earnings Call Highlights: Stent Graft Momentum and Nexus Launch ...
      Nov 6Yahoo FinanceAORTCRY
      What Artivion (AORT)'s Revenue Growth And Loss Mean For Shareholders
      Nov 6Yahoo FinanceAORTCRY
      Artivion (AORT) Q3 2026 Earnings Call Transcript
      Nov 6The Globe and MailAORTCRY
      Artivion Q3 2026 Earnings Call Transcript
      Nov 5BenzingaAORTCRY
      Artivion (AORT) Lags Q3 Earnings Estimates

      Artivion (AORT) delivered earnings and revenue surprises of -27.27% and +1.97%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 5Yahoo FinanceAORTCRY
      Artivion’s (NYSE:AORT) Q3 2026 sales beat estimates

      Medical device company Artivion (NYSE:AORT) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 9.2% year on year to $123.8 million. On the other hand, the company’s full-year revenue guidance of $488 million at the midpoint came in 0.5% below analysts’ consensus estimates. Its non-GAAP profit of $0.08 per share was 21.2% above analysts’ consensus estimates.

      Nov 5Yahoo FinanceAORTCRY
      Medical devices & supplies - cardiology, neurology, vascular stocks Q2 teardown: Artivion (NYSE:AORT) vs the rest
      Oct 22Yahoo FinanceAORTCRY
      Why is Artivion stock rallying today?
      Oct 20Investing.comAORTCRY
      Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’
      Oct 20Investing.comAORTCRYJEF
      Jefferies Initiates Artivion at Buy With $31 Price Target
      Oct 20Yahoo FinanceAORTCRY
      Jefferies initiates Artivion stock coverage with buy rating on product launches
      Oct 20Investing.comAORTCRY
      Transcript: Artivion Q2 2026 Earnings Conference Call - Artivion (NYSE:AORT)

      Artivion (NYSE:AORT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our

      Oct 12BenzingaAORTCRY
      Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem

      On August 6, Artivion Inc. (NYSE:AORT) reported second-quarter 2026 results that read as if two different companies wrote them. Revenue for the quarter ended June 30 climbed 11% on a GAAP basis to $125.8 million, and the company finished assembling what it calls the only complete aortic arch portfolio in its industry. Yet the same […]

      Sep 16Yahoo FinanceAORTCRY
      Artivion SVP Andrew Green sells $286k in company shares
      Sep 11Investing.comAORTCRY
      Artivion Insider Sold Shares Worth $286,656, According to a Recent SEC Filing

      Andrew M Green, Senior Vice President, Regulatory and Quality, on September 10, 2026, sold 11,480 sh

      Sep 11Yahoo FinanceAORTCRY
      Artivion SVP Andrew Green sells $216k in stock
      Sep 4Investing.comAORTCRY
      Artivion (AORT) Stock Looks Cheap On Cash Flow But Pricey On Sales

      Artivion stock has delivered a 57.6% gain over the past three years, yet current valuation checks suggest the shares now sit close to their estimated intrinsic value, rather than offering a clear discount. With the Discounted Cash Flow (DCF) estimate and market multiples both pointing to pricing that looks broadly in line with fundamentals, the stock no longer looks obviously cheap or obviously expensive. Artivion is up 57.6% over three years. This means anyone looking at the stock today is...

      Aug 27Yahoo FinanceAORTCRY
      Artivion (AORT) Bounces As AMDS Launch Narrative Keeps Fair Value In Focus

      Artivion (AORT) has drawn fresh attention after recent share price swings, with the stock up 3.1% in the latest session but still down 38.8% year to date as of 27 August 2026. Artivion’s recent 1 day share price return of 3.11% comes after a 7 day share price decline of 5.62%, with the stock still showing a year to date share price loss of 38.82%. The 3 year total shareholder return is 55.25%, suggesting longer term holders have seen a very different experience to recent buyers. Balance...

      Aug 27Yahoo FinanceAORTCRY

      This is the newest page. Registered accounts read further back.